BioSpace News Archive

Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET

Evofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives to senior Biden Administration officials calling for action to ensure coverage for the full range of contraceptives under the Affordable Care Act (ACA).

H3 Biomedicine Inc. today announced it will be providing an update on its intratumoral E7766 clinical program for advanced solid tumors or lymphomas in a poster presentation at the 2021 American Association for Cancer Research

Alpha Tau Medical is pleased to announce that it has received Breakthrough Device Designation for Alpha DaRT from the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent glioblastoma multiforme (GBM).

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately.

Turning Point Therapeutics, Inc. today announced the presentation of early clinical data from the NTRK-positive TKI-naïve and TKI-pretreated advanced solid tumor cohorts (EXP-5 and EXP-6) of the ongoing TRIDENT-1 Phase 1/2 study of its lead drug candidate repotrectinib.

Specialty Pharmacy Nursing Network, Inc (SPNN), a national provider of specialty home infusion nursing services is pleased to announce that Cheryl Allen , BS Pharm, MBA has joined the company as EVP Business Development. Before joining SPNN, Cheryl was EVP Business Development and Industry Relations at Asembia and Principal Consu

Cidara Therapeutics, Inc. (Nasdaq: CDTX), today announced the pricing of concurrent but separate underwritten public offerings of 14,838,706 shares of its common stock at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

Rigel Pharmaceuticals, Inc. reported the grant of stock options to purchase an aggregate of 469,000 shares of common stock to 23 newly hired employees.